Literature DB >> 7905126

Creutzfeldt-Jakob disease and blood transfusion.

N Heye, S Hensen, N Müller.   

Abstract

Entities:  

Mesh:

Year:  1994        PMID: 7905126     DOI: 10.1016/s0140-6736(94)91148-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies.

Authors:  K Wilson; C Code; M N Ricketts
Journal:  BMJ       Date:  2000-07-01

3.  New variant Creutzfeldt-Jakob disease and the blood supply: is it time to face the music?

Authors:  J Hoey; A Giulivi; A M Todkill
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 4.  Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians.

Authors:  C MacKnight; K Rockwood
Journal:  CMAJ       Date:  1996-09-01       Impact factor: 8.262

Review 5.  Is Creutzfeldt-Jakob disease transmitted in blood?

Authors:  M N Ricketts; N R Cashman; E E Stratton; S ElSaadany
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

6.  Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.

Authors:  S M King; H Watson; H Heurter; M Ricketts; S Elsaadany
Journal:  CMAJ       Date:  1998-10-06       Impact factor: 8.262

Review 7.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.